135575-42-7 | Pneumocandin b0

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
5mg	98%	in stock	$9.00	$6.00
10mg	98%	in stock	$16.00	$11.00
100mg	98%	in stock	$26.00	$18.00
1g	98%	in stock	$134.00	$94.00

Description

• Catalog Number: AD72408
• Chemical Name: Pneumocandin b0
• CAS Number: 135575-42-7
• Molecular Formula: C39H61N7O8
• Molecular Weight: 755.9437
• MDL Number: MFCD28168025
• SMILES: CCC(CC(CCCCCCCCC(=O)N[C@H]1C[CH][CH]NC(=O)[C@@H]2[CH]CCN2C(=O)[CH]NC(=O)[CH]NC(=O)[C@H]2N(C(=O)[C@@H](NC1=O)[C@H](O)C)C[CH]C2)C)C

Computed Properties

• Complexity: 1930
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 14
• Heavy Atom Count: 75
• Hydrogen Bond Acceptor Count: 17
• Hydrogen Bond Donor Count: 15
• Rotatable Bond Count: 20
• Undefined Atom Stereocenter Count: 2
• XLogP3: 0.5

Literature

• Synthesis of the antifungal beta-1,3-glucan synthase inhibitor CANCIDAS (caspofungin acetate) from pneumocandin B0.

  The Journal of organic chemistry 20070330

• Preparation and evaluation of novel stationary phases for improved chromatographic purification of pneumocandin B0.

  Journal of chromatography. A 20060106

• Influence of mobile phase composition and thermodynamics on the normal phase chromatography of echinocandins.

  Journal of chromatography. A 20051209

• Novel proline hydroxylase activities in the pneumocandin-producing fungus Glarea lozoyensis responsible for the formation of trans 3- and trans 4-hydroxyproline.

  Applied microbiology and biotechnology 20030801

• Determination of the relative and absolute configuration of the dimethylmyristoyl side chain of pneumocandin B0 by asymmetric synthesis.

  Organic letters 20021128

• Effects of amino acid and trace element supplementation on pneumocandin production by Glarea lozoyensis: impact on titer, analogue levels, and the identification of new analogues of pneumocandin B(0).

  Journal of industrial microbiology & biotechnology 20010401

• The effects of antifungal agents on the morphogenetic transformation by Candida albicans in vitro.

  The Journal of antimicrobial chemotherapy 19961001

• New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.

  Journal of medicinal chemistry 19951124

• New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat.

  Antimicrobial agents and chemotherapy 19950601

• In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373.

  Antimicrobial agents and chemotherapy 19950501

• Pneumocandin D0, a new antifungal agent and potent inhibitor of Pneumocystis carinii.

  The Journal of antibiotics 19940701

• Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.

  Journal of medicinal chemistry 19940121

• Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats.

  Antimicrobial agents and chemotherapy 19920901

• Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP).

  Journal of medicinal chemistry 19920101